Table 1 Baseline demographics and disease characteristics (Safety population)
From: Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
Parameter | Patients (N = 61) |
|---|---|
Age (years), mean (SD) | 66.0 (6.1) |
Male gender, n (%) | 43 (70.5) |
Race, n (%) | |
Caucasian | 60 (98.4) |
Asian | 1 (1.6) |
BMI (kg/m2), mean (SD) | 26.0 (4.3) |
Time since first COPD diagnosis (years), mean (range) | 9.51 (1.8 to 21.0) |
Smoking status at screening, n (%) | |
Ex-smoker | 27 (44.3) |
Current smoker | 34 (55.7) |
Post-bronchodilator FEV1 (L), mean (SD) | 1.30 (0.42) |
Post-bronchodilator FEV1 (% predicted), mean (SD) | 50.2 (11.8) |
50 to 70% predicted, n (%) | 33 (54.1) |
30 to 50% predicted, n (%) | 28 (45.9) |
COPD Assessment Test, mean (SD) | 20.7 (5.8) |
Baseline Dyspnea Index, mean (SD) | 6.2 (1.9) |
Sputum characteristics, mean (SD) | |
Total cell count (× 106/g) | 5.69 (20.26) |
Neutrophil cell count (× 106/g) | 4.82 (8.04) |
Macrophage cell count (×106/g) | 0.354 (0.319) |
Eosinophil cell count (× 106/g) | 0.142 (0.230) |
Lymphocyte cell count (×106/g) | 0.007 (0.011) |
Neutrophil % | 82.7 (9.46) |
Macrophage % | 11.0 (7.81) |
Eosinophil % | 3.60 (4.27) |
Lymphocyte % | 0.180 (0.267) |
Epithelial cells % | 2.50 (3.80) |